Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings

Charles Mulamba, Chris Williams, Katharina Kreppel, Jean Bosco Ouedraogo, Ally I. Olotu

Research output: Contribution to journalA1: Web of Science-articlepeer-review

13 Downloads (Pure)


Malaria control relies heavily on the use of anti-malarial drugs and insecticides against malaria parasites and mosquito vectors. Drug and insecticide resistance threatens the effectiveness of conventional malarial interventions; alternative control approaches are, therefore, needed. The development of malaria transmission-blocking vaccines that target the sexual stages in humans or mosquito vectors is among new approaches being pursued. Here, the immunological mechanisms underlying malaria transmission blocking, status of Pfs25-based vaccines are viewed, as well as approaches and capacity for first in-human evaluation of a transmission-blocking candidate vaccine Pfs25-IMX313/Matrix-M administered to semi-immune healthy individuals in endemic settings. It is concluded that institutions in low and middle income settings should be supported to conduct first-in human vaccine trials in order to stimulate innovative research and reduce the overdependence on developed countries for research and local interventions against many diseases of public health importance.

Original languageEnglish
Article number159
JournalMalaria Journal
Issue number1
Pages (from-to)159
Number of pages15
Publication statusPublished - 2022
Externally publishedYes


  • Animals
  • Humans
  • Insecticide Resistance
  • Malaria Vaccines
  • Mosquito Vectors
  • Nanoparticles
  • Saponins


Dive into the research topics of 'Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings'. Together they form a unique fingerprint.

Cite this